Interaction with Type II Estrogen Binding Sites and Antiproliferative Activity of Tamoxifen and Quercetin in Human Non-Small-Cell Lung Cancer

American Journal of Respiratory Cell and Molecular Biology

Volumn 17, Issue 1, 1997, Pages 51-59

  Caltagirone, Sara ^b   Ranelletti, Franco O ^b   Rinelli, Alessandro ^b   Maggiano, Nicola ^b   Colasante, Antonella ^b   Musiani, Piero ^b   Aiello, Francesca B ^b   Piantelli, Mauro ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DNA; ESTRADIOL; ESTROGEN BINDING SITE, TYPE II; ESTROGEN RECEPTOR; IPRIFLAVONE; ISOFLAVONE DERIVATIVE; QUERCETIN; RUTOSIDE; TAMOXIFEN;

AGED; ANIMAL; ARTICLE; BINDING COMPETITION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CELL LINE; CELL NUCLEUS; CYTOSOL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; KINETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RAT;

AGED; ANALGESICS; ANIMALS; BINDING, COMPETITIVE; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE; CELL NUCLEUS; CYTOSOL; DNA, NEOPLASM; ESTRADIOL; FEMALE; HUMANS; ISOFLAVONES; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUERCETIN; RATS; RECEPTORS, ESTROGEN; RUTIN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031183507     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.17.1.2728     Document Type: Article

References (47)

1. Canver, C. C., V. A. Memoli, P. L. Vanderveer, C. A. Dingivan, and R. M. Mentzer, Jr. 1994. Sex hormone receptors in non-small-cell lung cancer in human beings. J. Thorac. Cardiovasc. Surg. 108:153-157.
2. Ollayos, C. W., O. P. Riordan, and J. M. Rushin. 1994. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch. Pathol. Lab. Med. 118:630-632.
3. Cagle, P. T., D. R. Mody, and M. R. Schwartz. 1990. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res. 50:6632-6635.
4. Kirk, J., S. Houlbrook, N. S. Stuart, I. J. Stratford, A. L. Harris, and J. Carmichael. 1993. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur. J. Cancer 29A:1152-1157.
5. Kirk, J., S. Houlbrook, N. S. Stuart, I. J. Stratford, A. L. Harris, and J. Carmichael. 1993. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br. J. Cancer 67:1189-1195.
6. McClay, E., K. D. Albright, J. A. Jones, R. D. Christen, and S. B. Howell. 1993. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int. J. Cancer 55:1018-1022.
7. Croxtall, J. D., C. Emmas, J. O. White, O. Choudhary, and R. Flower. 1994. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol. 47:197-202.
8. Markaverich, B. M., and J. H. Clark. 1979. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotrophic response. Endocrinology 105:1458-1462.
9. Syne, J. S., B. M. Markaverich, J. H. Clark, and W. B. Panko. 1982. Estrogen binding sites in the nucleus of normal and malignant tissue: characteristics of the multiple binding sites. Cancer Res. 42:4449-4454.
10. Markaverich, B. M., R. R. Roberts, M. A. Alejandro, G. A. Johnnan, B. S. Middleditch, and J. H. Clark. 1988. Bioflavonoid interaction with rat uterine type II binding sites and growth inhibition. J. Steroid Biochem. 30:71-78.
11. Markaverich, B. M., R. R. Gregory, M. A. Alejandro, F. S. Kittrel, D. Medina, J. H. Clark, M. Varma, and R. S. Varma. 1990. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 50:1470-1478.
12. Gabor, M. 1988. Szent-Györgyi and the bioflavonoids: new results and perspectives of pharmacological research into benzo-pyrone derivatives. In Plant Flavonoids in Biology and Medicine. II: Biochemical, Cellular, and Medical Properties. Progress in Clinical and Biological Research, Vol. 280. V. Cody, F. Middleton, Jr., J. B. Harbone, and A. Beretz, editors. Alan R. Liss, New York. 1-15.
13. Scambia, G., F. O. Ranelletti, P. Benedetti Panici, M. Piantelli, G. Bonanno, R. De Vincenzo, G. Ferrandina, C. Rumi, L. M. Larocca, and S. Mancuso. 1990. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br. J. Cancer 62:942-946.
14. Ranelletti, F. U., R. Ricci, L. M. Larocca, N. Maggiano, A. Capelli, G. Scambia, S. Mancuso, C. Rumi, and M. Piantelli. 1992. Growth-inhibitory effect of quercetin and presence of type II estrogen-binding sites in human colon-cancer cell lines and primary tumors. Int. J. Cancer 50:486-492.
15. Larocca, L. M., L. Teofili, G. Leone, S. Sica, G. Menichella, G. Scambia, P. Benedetti Panici, R. Ricci, M. Piantelli, and F. O. Ranelletli. 1991. Antiproliferative activity of quercetin on normal hone marrow and leukaemic progenitors. Br. J. Haematol. 79:562-566.
16. Piantelli, M., N. Maggiano, R. Ricci, L. M. Larocca, A. Capelli, G. Scambia, G. Isola, P. G. Natali, and F. O. Ranelletti. 1995. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J. Invest. Dermatol. 105:248-253.
17. Scambia, G., F. O. Ranelletti, P. Benedetti Panici, M. Piantelli, G. Bonanno, R. De Vincenzo, G. Ferrandina, A. Capelli, and S. Mancuso. 1991. Quercetin inhibits the growth of a multidrug-resistant, estrogen-receptor-negative MCF-7 human breast cancer cell line expressing type II estrogen binding sites. Cancer Chemother. Pharmacol. 28:255-258.
18. Scambia, G., F. O. Ranelletti, P. Benedetti Panici, M. Piantelli, C. Rumi, F. Battaglia, L. M. Larocca, A. Capelli, and S. Mancuso. 1991. Type II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids. Int. J. Cancer 46:1112-1116.
19. Piantelli, M., R. Ricci, L. M. Larocca, A. Rinelli, A. Capelli, S. Rizzo, G. Scambia, and F. O. Ranelletti. 1990. Type II oestrogen binding sites in human colorectal carcinoma. J. Clin. Pathol. 43:1004-1006.
20. Burton, K. 1956. A study of the condition and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:315-318.
21. Berthois, Y., J. A. Katzellenbogen, and B. S. Katzellenbogen. 1986. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen responsive cells in culture. Proc. Natl. Acad. Sci. USA 83:2496-2500.
22. Chander, S. K., S. S. Sahota, T. R. J. Evans, and Y. A. Luqmani. 1993. The biological evaluation of novel antiestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 15:243-269.
23. Feucht, K. A., M. J. Walker, T. K. Das Gupta, and G. W. Beattie. 1988. Effect of 17β-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res. 48:7093-7101.
24. Gill, P. G., N. J. De Young, A. Thompson, D. D. Keightley, and D. J. Horsfall. 1984. The effect of tamoxifen on the growth of human malignant melanoma in vitro. Eur. J. Clin. Oncol. 20:807-815.
25. O'Brian, C. A., N. E. Ward, and B. W. Anderson. 1988. Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J. Natl. Cancer Inst. 80:1628-1633.
26. Darbre, P. D., S. Curtis, and R. J. B. King. 1984. Effects of estradiol and tamoxifen on human cancer cells in serum-free culture. Cancer Res. 44: 2790-2793.
27. Su, H. D., G. J. Mazzei, W. R. Vogler, and J. F. Kua. 1985. Effects of tamoxifen a non steroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorilation of its endogenous substrate proteins from rat brain and ovary. Biochem. Pharmacol. 34:3649-3653.
28. Grunicke, H., J. Hofmann, K. Maly, F. Uberall, L. Posch, H. Oberhuber, and H. Fiebig. 1989. The phospholipid and calcium dependent protein kinase as a target in tumor chemotherapy. Adv. Enzyme Regul. 28:201-210.
29. Couldwell, W. T., D. R. Hinton, S. He, T. C. Chen, I. Sebat, M. H. Weiss. and E. Lawr. 1994. Protein kinase inhibitors induce apoptosis in human malignant glioma cell line. FEBS Lett. 345:43-46.
30. Wei, Y. Q., X. Zhao, Y. Kariya, H. Fukat, K. Teshigawara, and A. Uchida. 1994. Induction of apoptosis by quercetin: involvement of heat-shock protein. Cancer Res. 54:4952-4957.
31. McClay, E. F., K. D. Albright, J. A. Jones, R. D. Christen, and S. B. Howell. 1994. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br. J. Cancer 70:449-452.
32. Scambia, G., F. O. Ranelletti, P. Benedetti, M. Piantelli, R. De Vincenzo, G. Bonanno, G. Ferrandina, G. Isola, and S. Mancuso. 1992. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur. J. Cancer 28:1885-1889.
33. Hofmann, J., H. H. Fiebig, B. R. Winterhalter, D. P. Berger, and H. Grunicke. 1990. Enhancement of the antiproliferative activity of cis-diamine-dichloro-platinum by quercetin. Int. J. Cancer 45:536-539.
34. Kirk, J., S. K. Syed, A. L. Harris, M. Jarman, B. D. Roufogalis, and I. J. Carmichael. 1994. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-estrogens and novel tamoxifen derivatives. Biochem. Pharmacol. 48:277-285.
35. Lien, E. A., E. Solheim, and P. M. Ueland. 1991. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51:4837-4842.
36. Gugler, R., M. Leschik, and M. J. Dengler. 1975. Disposition of quercetin in man after single oral and intravenous doses. Eur. J. Clin. Pharmacol. 9: 229-235.
37. Verma, A., G. A. Johnson, M. N. Gould, and M. A. Tanner. 1988. Inhibition of 7,12-dimethyl-benzoanthracene- and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res. 48:5754-5758.
38. Haenszel, W., F. B. Locke, and M. Segi. 1980. A case control study of large-bowel cancer in Japan. J. Natl. Cancer Inst. 64:17-22.
39. Graham, S., H. Dayal, and M. Swanson. 1978. Diet in the epidemiology of cancer of the colon and rectum. J. Natl. Cancer Inst. 51:709-714.
40. Adlerkreutz, H. 1984. Does fiber-rich food containing animal lignan precursors protect against both colon and breast cancer? An extension of the "fiber hypothesis." Gastroenterology 86:761-766.
41. Wattenberg, L. 1995. Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. J. Cell Biochem. 22:162-168.
42. Ferry, D. R., A. Smith, J. Malkhandi, D. W. Fyfe, P. G. deTakats, D. Anderson, J. Baker, and D. J. Kerr. 1996. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo thyrosine kinase inhibition. Clin. Cancer Res. 2:659-668.
43. Knabbe, C., M. E. Lippman, L. M. Wakefield, K. C. Flanders, A. Kasid, R. Derynck, and R. B. Dickson. 1987. Evidence that TGF-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428.
44. Scambia, G., P. Benedetti, F. O. Ranelletti, G. Ferrandina, R. DeVincenzo, M. Piantelli, V. Masciullo, G. Bonanno, G. Isola, and S. Mancuso. 1994. Quercetin enhances transforming growth factor β1 secretion by human ovarian cancer cells. Int. J. Cancer 57:211-215.
45. Larocca, L. M., L. Teofili, S. Sica, M. Piantelli, N. Maggiano, G. Leone, and F. O. Ranelletti. 1995. Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor β1 in these cells. Blood 85:3654-3661.
46. Pelton, R. W., and H. L. Moses. 1990. The beta-type transforming growth factor. Am. Rev. Respir. Dis. 142(Suppl.):S31-S35.
47. Jakowlew, S. B., M. Askale, P. Chung, and T. W. Moody. 1995. Expression of transforming growth factor β ligand and receptor messengers RNAs in lung cancer cell lines. Cell Growth Differ. 6:465-476.